251 Consumers Road
142 articles with Aptose Biosciences
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million.
All of the common shares to be sold in the proposed offering will be sold by the Company.
Aptose Biosciences Inc. announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.
Aptose Biosciences Inc. released highlights from a corporate event and clinical update held at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of Senior Vice President, Chief Medical Officer, effective January 1, 2020.
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 31st Annual Piper Jaffray Healthcare Conference at the Lotte Palace Hotel in New York.
Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 25th Annual International BIO-Europe Partnering Conference, being held November 11th -13th in Hamburg, Germany. Aptose will be presenting and hosting 1x1 meetings.
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company will be hosting an Event at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2019 in Orlando, FL.
Aptose Biosciences Inc. announced financial results for the three months ended September 30, 2019 and reported on corporate developments.
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
Aptose Biosciences Inc., a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the second quarter ended September 30, 2019 on Tuesday, November 5, 2019 after the close of the market.
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
Aptose Biosciences Inc. announced that William G. Rice, Ph.D., Chairman, President and CEO, and Jotin Marango, M.D., Ph.D., Senior VP and CBO, will participate at the 5th International Conference on Acute Myeloid Leukemia “Molecular and Translational” Advances in Biology and Treatment, and present preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, in a poster presentation on October 24th, 2019 in Estoril, Portugal.
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...
The Preliminary Shelf Prospectus and corresponding shelf registration statement have not yet become final or effective.
Orphan drug designation provides Aptose certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
Data elucidate unique ability of CG’806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents.
The net loss for the quarter ended September 30, 2017 was $3.3 million ($0.14 per share) compared with $4.0 million ($0.31 per share) in the quarter ended September 30, 2016.
Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017
The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.
Aptose also provided a corporate update on the development of its two hematology drug candidates.